Pascale Schneider

Prof. Pascale Schneider


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Leukemia Research
Verified
Journal Article
Closed access
PSPascale Schneider
Pascale Schneider
OCOdile Costa
Odile Costa
ELElisabeth Legrand
Elisabeth Legrand
DBDany Bigot
Dany Bigot
SLSylviane Lecleire
Sylviane Lecleire
Marc VasseMarc Vasse
Marc Vasse

9 November 2011 in Advances in Hematology
Verified
Journal Article
Open access
PDF file
PSPascale Schneider
Pascale Schneider
IDI. Dubus
I. Dubus
FGF. Gouel
F. Gouel
ELE. Legrand
E. Legrand
JVJ. P. Vannier
J. P. Vannier
Marc VasseMarc Vasse
Marc Vasse
The role of angiogenesis in acute leukaemia has been discussed since the cloning of the gene ofvascular endothelial growth factor(VEGF) from the acute myelogenous leukemia cell line (HL60) and, thereafter, when the first studies reported increased bone marrow vascularity and elevation of angiogenic cytokines in acute lymphoblastic leukaemia (ALL). VEGF andbasic fibroblast growth factor(bFGF) are the major proangiogenic cytokines that have been studied, and evaluation of their prognostic impact in childhood ALL has been reported in several studies, though with controversial results. The antiangiogenic response, contributing to the angiogenic balance, has scarcely been reported. The origin of the factors, their prognostic value, and their relevance as good markers of what really happens in the bone marrow are discussed in this paper. The place of antiangiogenic drugs in ALL has to be defined in the global treatment strategy.

1 August 2014 in Clinical Proteomics
Verified
Journal Article
Open access
PDF file
OCOdile Costa
Odile Costa
PSPascale Schneider
Pascale Schneider
LCLaurent Coquet
Laurent Coquet
PCPhilippe Chan
Philippe Chan
DPDominique Penther
Dominique Penther
JVJean-Pierre Vannier
Jean-Pierre Vannier
Until now, the major prognostic factors for pediatric acute lymphoblastic leukemia (ALL), age, white blood cell count and chromosomal alterations are initially taken into account for the risk stratification of patients. In the light of protein marker studies to classify subtypes of Acute Myeloblastic Leukemia efficiently, we have compared the lymphoblastes proteome in Childhood ALL in accordance with the presence of t(12;21), indicator of good prognosis, usually.

3 May 2001 in Medical and Pediatric Oncology
Verified
Journal Article
Closed access
PDF file
AMAude Marie-Cardine
Aude Marie-Cardine
PSPascale Schneider
Pascale Schneider
JMJosette Metayer
Josette Metayer
BBBruno Bachy
Bruno Bachy
JVJean-Pierre Vannier
Jean-Pierre Vannier
VGValérie Greene
Valérie Greene

23 September 2015 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BFBruno Filhon
Bruno Filhon
BLBoris Lacarra
Boris Lacarra
CHCharles Hervouet
Charles Hervouet
MJMarie Jaffray
Marie Jaffray
PSPascale Schneider
Pascale Schneider
JVJean-Pierre Vannier
Jean-Pierre Vannier

1 April 2013
Verified
Journal Article
Closed access
NRNathalie Rives
Nathalie Rives
JMJean-Pierre Milazzo
Jean-Pierre Milazzo
ATAlbanne Travers
Albanne Travers
BABrahim Arkoun
Brahim Arkoun
ABAmandine Bironneau
Amandine Bironneau
BMBertrand Macé
Bertrand Macé